Skip to main content
SpringerLink
Log in

Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Alzheimer's disease (AD) and senile dementia (SD) are often classified together, but there are genetic, biochemical, neuropathological and clinical arguments for separating them.

The well-known Alzheimer lesions in the brains of patients with AD and SD are described, as is the loss of neurons in the locus coeruleus. White matter changes in brains from patients with dementia are discussed and related to AD and SD.

Biochemical changes in brains of patients with AD and SD include reduced activity of acetylcholineesterase (AChE) and choline-acetyltransferase (CAT), indicating reduced activity in the acetylcholinergic system. There is also, however, reduced activity in the dopamine (DA), noradrenaline (NA) and 5-hydroxytryptamine (5-HT) system. The active amines are decreased while the end metabolites are decreased to a lesser extent or normal. The levels of the active amines are thought to reflect the number of neurons, while the levels of end metabolites reflect the rate of turnover in the system. 3-Methoxy-4-hydroxyphenylglycol (MHPG) is increased to levels above normal, which may indicate an increased rate of turnover in the NA system.

Monoamine oxidase B (MAO-B), which is increased in advanced age, is further increased in patients with AD and SD. It is assumed that this enzyme is localized in extraneuronal tissue, and therefore the increase may reflect a gliosis.

In brains from patients with AD and SD neuropeptides are also studied. Only somatostatin and substance P, however, seem to be reduced, indicating selective damage to the neuropeptides.

The biochemical changes can be given pathogenetic importance. Disturbances in the acetylcholinergic system may explain memory disturbances, disturbances in the DA system may explain parkinsonlike symptoms and disturbances in the NA and 5-HT systems may explain mood disturbances and emotional symptoms in the disorder. The biochemical changes may also suggest a line of treatment. At present, several attempts have been made to activate the neurotransmitter systems. The progress of these studies is, however, not very encouraging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135:216–223

    Google Scholar 

  • Adolfsson R, Gottfries CG, Oreland L, Wiberg Å, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27:1029–1034

    Google Scholar 

  • Adolfsson R, Gottfries CG, Nyström L, Winblad B (1981) Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand 63:225–244

    Google Scholar 

  • Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Cbl Nervenheilk Psychiat, 18: 177–179. Cited by Torack R (1971) In: Wells C (ed) Dementia, FA Davis Co, Philadelphia

    Google Scholar 

  • Arai H, Kosaka K, Iizuka R (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43:388–393

    Google Scholar 

  • Blessed G, Cross AJ, Crow TJ, Perry EK, Perry RH, Tomlinson BE (1982) Monoaminergic changes in post-mortem brain in Alzheimer-type senile dementia. In: Abstracts, vol 1, Collegium Internationale Neuro-Psychopharmacologicum, 13th C.I.N.P. Congress, Jerusalem, Israel, June 20–25, 1982, p 57

  • Bondareff W, Mountjoy CQ, Roth M (1981) Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus caeruleus) in senile dementia. Lancet 1:783–784

    Google Scholar 

  • Bowen DM, Flack RHA, White P, Smith CB, Davison AN (1974) Brain-decarboxylase activities as indices of pathological changes in senile dementia. Lancet 1:1247–1249

    Google Scholar 

  • Bowen DM, Spillane JA, Curzon G, Meier-Ruge W, White P, Goodhardt MJ, Iwangoff P, Davison AN (1979) Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet 1:11–14

    Google Scholar 

  • Brun A (1983) An overview of light and electron microscopic changes. In: Reisberg B (ed) Alzheimer's disease. The Free Press, New York London, pp 37–47

    Google Scholar 

  • Brun A, Gustafson L (1978) Limbic lobe involvement in presenile dementia. Arch Psychiatr Nervenkr 226:76–93

    Google Scholar 

  • Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403

    Google Scholar 

  • Davies P, Terry RD (1981) Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiol Aging 2:9–14

    Google Scholar 

  • Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288:279–280

    Google Scholar 

  • Davies P, Katz DA, Crystal HA (1982) Choline acetyltransferase, somatostatin, and substance P in selected cases of Alzheimer's disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtsman RJ (eds) Aging, Vol. 19: Alzheimer's disease. A report of progress in research. Raven Press, New York, pp 9–14

    Google Scholar 

  • Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30:113–121

    Google Scholar 

  • Gajdusek C (1984) Transmissible agents. Lecture held at the Symp. “Physiological aging and dementia of Alzheimer type (AD/SDAT)”, 14th Collegium International Neuropsychopharmacologicum Congress, June 19–23, Florence, Italy

  • Gellerstedt N (1933) Zur Kenntnis der Hirnveränderungen bei der normalen Altersinvolution. Uppsala Läk Fören Förh 38

  • Gottfries CG (1981) Levels of monoamines, monoamine metabolites, and activity in releated enzyme systems correlated to normal aging and in patients with dementia of Alzheimer type. In: Corsini GU, Gessa GL (eds) Apomorphine and other dopaminomimetics. Vol. 2: Clinical Pharmacology. Raven Press, New York, pp 243–249

    Google Scholar 

  • Gottfries CG (1983a) Biochemical changes in blood and cerebrospinal fluid. In: Reisberg B (ed) Alzheimer's disease. The standard reference. The Free Press, Collier McMillan Publishers, London, pp 122–130

    Google Scholar 

  • Gottfries CG (1983b) Dementia. In: Hippius H, Winokur G (eds) Psychopharmacology 1, Part 2: Clinical psychopharmacology. Excerpta Medica, Amsterdam, pp 271–285

    Google Scholar 

  • Gottfries CG (1984a) Senile dementia of the Alzheimer's type: Clinical, genetic, pathogenetic and treatment aspects. Presented at the International Conference of Life-Span Research, September 16–21, 1982, Berlin (In press)

  • Gottfries CG (1984b) Treatment with monoaminergic drugs in Alzheimer's disease and senile dementia. Lecture held at the Symposium “Physiological aging and dementia of Alzheimer type (AD/SDAT)”, 14th Collegium Internationale Neuropsychopharmacologicum, June 19–23, 1984, Florence, Italy

  • Gottfries CG, Gottfries I, Roos BE (1969) The investigation of homovanillic acid in the human brain and its correlation to senile dementia. Br J Psychiatry 115:563–574

    Google Scholar 

  • Gottfries CG, Gottfries I, Ross, BE (1970) Homovanillic acid and 5-hydroxyindolacetic acid in cerebrospinal fluid related to rated mental and motor impairment in senile and presenile dementia Acta Psychiatr Scand 46:99–105

    Google Scholar 

  • Gottfries CG, Roos BE, Winblad B (1976) Monoamine and monoamine metabolites in the human brain post mortem in senile dementia. Aktuel Gerontol 6:429–435

    Google Scholar 

  • Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Oreland L, Svennerholm L, Winblad B (1980) Parkinsonism and dementia disorders of Alzheimer type: Similarities and differences. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson's disease — Current progress, problems and management. Elsevier/North Holland Biomedical Press, Amsterdam, pp 197–208

    Google Scholar 

  • Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernäs SÅ, Nordberg A, Oreland L, Svennerholm L, Wiberg Å, Winblad B (1983) Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4:261–271

    Google Scholar 

  • Gottfries CG, Karlsson I, Svennerholm L (1984) Senile dementia — a white matter disease. Lecture held at the Symposium “Physiological aging and dementia of Alzheimer type (AD/SDAT)” 14th Collegium Internationale Neuropsychopharmacologicum, June 19–23, 1984, Florence, Italy

  • Janota I (1981) Dementia, deep white matter damage and hypertension: “Binswanger's disease”. Psychol Med 11:39–48

    Google Scholar 

  • Karlsson I, Gottfries CG (1982) CSF monoamine metabolites in early and late dementia of Alzheimer type. Poster presented at The Tenth Aharon Katzir-Katchalsky Conference on the Aging of the Brain, March 26–29, 1982, Mantova, Italy

  • Larsson T, Sjögren T, Jacobson G (1963) Senile dementia. A clinical, sociomedical and genetic study. Acta Psychiatr Scand, Suppl 167

  • Lehmann J, Persson S, Wålinder J, Wallin L (1981) Tryptophan malabsorption in dementia. Improvement in certain cases after tryptophan therapy as indicated by mental behaviour and blood analysis. A pilot study. Acta Psychiatr Scand 64:123–131

    Google Scholar 

  • de Leon M (1984) White matter disturbances in dementia disorders as shown by NMR. Lecture held at the Symposium “Physiological aging and dementia of Alzheimer type (AD/SDAT)”, 14th Collegium Internationale Neuropsychopharmacologicum Congress, June 19–23, 1984, Florence, Italy

  • Loew DM, van Deusen EB, Meier-Ruge W (1978). Effect on the central nervous system. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Handbook of experimental pharmacology. Vol. 49. Springer, Berlin, pp 421–531

    Google Scholar 

  • Nielsen J (1962) Geronto-psychiatric period-prevalence investigation in a geographically delimited population. Acta Psychiatr Scand 38:307–330

    Google Scholar 

  • Obrist WD (1972) Cerebral physiology of the aged: Influence of circulatory disorders. In: Gaitz CM (ed) Aging and the brain. Plenum Press, New York, London, pp 117–133

    Google Scholar 

  • Oliveros JC, Jandali MD, Timsit-Berthier M, Remy R, Benghezal A, Audibert A, Moeglen JM (1978) Vasopressin in amnesia. Lancet 1:42

    Google Scholar 

  • Op den Velde W, Stam FC (1976) Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J Am Geriatr Soc 24, No. 1:12–16

    Google Scholar 

  • Oreland L (1984) Monoamine oxidase in normal aging and in AD/SDAT. Lecture held at the Symposium “Physiological aging and dementia of Alzheimer type (AD/SDAT)”, 14th Collegium Internationale Neuropsychopharmacologicum, June 19–23, 1984, Florence, Italy

  • Pearce J (1974) Mental changes in Parkinsonism. Br Med J Lett 1:445

    Google Scholar 

  • Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Letters to the editor. Lancet 1:189

    Google Scholar 

  • Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457–1459

    Google Scholar 

  • Pope A, Hess HH, Lewin E (1965) Neurochemical pathology of the cerebral cortex in presenile dementias. Trans Am Neurol Assoc 89:15–16

    Google Scholar 

  • Reisberg B ed (1983) Alzheimer's Disease. The standard reference The Free Press, Collier McMillan Publishers, London

    Google Scholar 

  • Rossor M, Fahrenkrug J, Emson P, Mountjoy C, Iversen L, Roth M (1980) Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide. Brain Res 201:249–253

    Google Scholar 

  • Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M (1984) Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J 288:961–964

    Google Scholar 

  • Sahgal A (1984) A critique of the vasopressin—memory hypothesis. Psychopharmacology 83:215–228

    Google Scholar 

  • Svanborg A, Landahl S, Mellström D (1983) In: Thomas H, Maddox GL (eds) New perspectives on old age. A message to decision makers. Springer Publishing Company, New York, pp 31–52

    Google Scholar 

  • White P, Hiley CR, Goodhardt MJ, Carrasco LH, Keet JP, Williams IEI, Bowen DM (1977) Neocortical cholinergic neurons in elderly people. Lancet 1:668–671

    Google Scholar 

  • Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia. Loss of neurons in the basal forebrain. Science 215:1237–1239

    Google Scholar 

  • de Wied D (1964) The influence of anterior pituitary on avoidance learning and escape behavior. Am J Physiol 207:255

    Google Scholar 

  • de Wied D (1969) Effects of peptide hormones on behavior. In: Ganong WF, Martini L (eds) Frontiers in neuroendocrinology. Oxford University Press, London, pp 97–140

    Google Scholar 

  • de Wied D (1974) Pituitary-adrenal system hormones and behavior. In: Schmitt FO, Warden FG (eds) The Neurosciences, Third Study Program. M. I. T. Press, Cambridge, MA, pp 653–666

    Google Scholar 

  • de Wied D, van Wimersma Greidanus TB, Bohus B, Urban I, Gispen WH (1976) Vasopressin and memory consolidation. Progr Brain Res 45:181

    Google Scholar 

  • Zigmond MJ, Acheson AL, Chiodo LA, Stricker EM (1981) Increased norepinephrine turnover and increased firing rate in residual neurons after ne-depleting lesions. Abstr Soc Neurosci 7:1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neurochemistry, St Jörgens Hospital, University of Göteborg, Sweden

    C. G. Gottfries

Authors
  1. C. G. Gottfries
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gottfries, C.G. Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology 86, 245–252 (1985). https://doi.org/10.1007/BF00432208

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00432208

Key words

Search

Navigation